Ocular toxicity of targeted therapies
DJ Renouf, JP Velazquez-Martin, R Simpson… - Journal of Clinical …, 2012 - ascopubs.org
Molecularly targeted agents are commonly used in oncology practice, and many new
targeted agents are currently being tested in clinical trials. Although these agents are …
targeted agents are currently being tested in clinical trials. Although these agents are …
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell–and patient-derived tumor organoids
There are few in vitro models of exocrine pancreas development and primary human
pancreatic adenocarcinoma (PDAC). We establish three-dimensional culture conditions to …
pancreatic adenocarcinoma (PDAC). We establish three-dimensional culture conditions to …
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Pancreatic adenocarcinoma presents as a spectrum of a highly aggressive disease in
patients. The basis of this disease heterogeneity has proved difficult to resolve due to poor …
patients. The basis of this disease heterogeneity has proved difficult to resolve due to poor …
Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial
EM O'Reilly, DY Oh, N Dhani, DJ Renouf… - JAMA …, 2019 - jamanetwork.com
Importance New therapeutic options for patients with metastatic pancreatic ductal
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …
Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series
J Cadranel, SV Liu, M Duruisseaux, E Branden… - The …, 2021 - academic.oup.com
Abstract Background Neuregulin 1 (NRG1) fusions, which activate ErbB signaling, are rare
oncogenic drivers in multiple tumor types. Afatinib is a pan‐ErbB family inhibitor that may be …
oncogenic drivers in multiple tumor types. Afatinib is a pan‐ErbB family inhibitor that may be …
Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer
L Fong, A Hotson, JD Powderly, M Sznol, RS Heist… - Cancer discovery, 2020 - AACR
Adenosine mediates immunosuppression within the tumor microenvironment through
triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this …
triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this …
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes
E Pleasance, E Titmuss, L Williamson, H Kwan… - Nature Cancer, 2020 - nature.com
Advanced and metastatic tumors with complex treatment histories drive cancer mortality.
Here we describe the POG570 cohort, a comprehensive whole-genome, transcriptome and …
Here we describe the POG570 cohort, a comprehensive whole-genome, transcriptome and …
Reasons for underuse of adjuvant chemotherapy in elderly patients with stage III colon cancer
Background Undertreatment has been frequently reported in the elderly cancer patient
population. For this reason, we aimed to characterize adjuvant chemotherapy (AC) use …
population. For this reason, we aimed to characterize adjuvant chemotherapy (AC) use …
[HTML][HTML] A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors
Objectives: SLC-0111 is an ureido-substituted benzenesulfonamide small molecule inhibitor
of carbonic anhydrase IX. The objectives of this first-in-human Phase 1 study were to …
of carbonic anhydrase IX. The objectives of this first-in-human Phase 1 study were to …
[HTML][HTML] The CCTG PA. 7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic …
Immunotherapy-based monotherapy treatment in metastatic pancreatic ductal
adenocarcinoma (mPDAC) has shown limited benefit outside of the mismatch repair …
adenocarcinoma (mPDAC) has shown limited benefit outside of the mismatch repair …